---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-002738"
form_type: "8-K"
ticker: "STAA"
cik: "0000718937"
company_name: "STAAR SURGICAL CO"
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:41:53.434556+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# STAAR Surgical prelim Q4 net sales ~$76.5M, ICL sales +22%; FY2024 outlook $335-340M

## Summary
- Preliminary FY2023 net sales ~$322.5M (+13% YoY); Q4 net sales ~$76.5M (+19% YoY).
- Global ICL sales up 22% in Q4 (APAC +26%) and 18% for FY2023; ICL unit growth outpaced refractive industry by 26 points in 2023.
- FY2024 net sales guidance of $335-340M, implying ~10% ICL growth in both China and U.S.; GAAP operating margin expected at least breakeven.
- Cash and investments ~$230M, up ~$28M from Q3; accounts receivable ~$90M.
- Full FY2023 results to be reported on or about Feb 21, 2024.

## SEC filing metadata
- accession: 0000950170-24-002738
- form_type: 8-K
- ticker: STAA
- cik: 0000718937
- company_name: STAAR SURGICAL CO
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/718937/000095017024002738/0000950170-24-002738-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/718937/000095017024002738/staa-20240108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-002738
- JSON: https://secwatch.observer/filing/0000950170-24-002738.json
- Plain text: https://secwatch.observer/filing/0000950170-24-002738.txt

## Key facts
- Earnings Releases
  STAAR SURGICAL CO reported fiscal year ended December 29, 2023 results: revenue Net sales of approximately $322.5 million for fiscal 2023 (preliminary). Guidance initiated.
  - Period: fiscal year ended December 29, 2023
  - Revenue: Net sales of approximately $322.5 million for fiscal 2023 (preliminary)
  - Guidance: initiated
  - Result: preliminary results
  source text: STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL) for myopia, astigmatism and presbyopia, today announced preliminary results for the fourth quarter and fiscal year ended December 29, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/718937/000095017024002738/0000950170-24-002738-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.